Dr. Ramaprasad Srinivasan on the HIF-2α inhibitor MK-6482 in VHL-associated RCC
Over 90% of patients in a phase 2 trial had at least some decrease in the size of target lesions.
Dr. Ramaprasad Srinivasan, MD, PhD, Urologic Oncology Branch, National Cancer Institute, discusses a phase 2 study of the investigational HIF-2α inhibitor MK-6482 in patients with Von Hippel-Lindau–associated renal cell carcinoma (RCC).
Results from the study shared during the 2020 Society of Urologic Oncology Annual Meeting showed that at a median follow-up of 68.7 weeks (range, 18.3-104.7), the objective response rate (ORR) in RCC lesions among 60 evaluable patients was 36.1%, comprising 22 confirmed partial responses (PRs). There were also 7 unconfirmed PRs. Overall, 91.8% (n = 56) of patients had at least some decrease in the size of target lesions.
Clinical activity with MK-6482 was also observed in non-RCC lesions. The confirmed ORR in pancreatic lesions was 63.9%, including 4 complete responses. The confirmed ORR in brain hemangioblastomas was 30.2%, with a CR rate of 11.6%. Also, 11 (68.8%) of 15 patients with retinal lesions demonstrated improvement in these lesions, with the 4 other patients reaching stable disease.
Mitochondrial metabolism may promote kidney cancer metastasis, new data show
August 14th 2024“The challenge now is to understand how these key aspects of mitochondrial metabolism become activated, why they stimulate metastasis, and whether we can safely block them,” says Ralph J. DeBerardinis, MD, PhD.
